Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Wednesday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of Brooklyn ImmunoTherapeutics stock opened at $2.40 on Wednesday. The stock has a market cap of $141.18 million, a price-to-earnings ratio of -1.06 and a beta of 4.61. The stock has a 50 day moving average price of $2.00 and a 200-day moving average price of $1.80. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10.

Hedge Funds Weigh In On Brooklyn ImmunoTherapeutics

An institutional investor recently raised its position in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC lifted its stake in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the quarter. Renaissance Technologies LLC owned about 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 at the end of the most recent reporting period. 26.00% of the stock is currently owned by institutional investors and hedge funds.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.